Symptomatic reversal of peripheral neuropathy in diabetic patients

Objective: There is no therapy which reverses peripheral neuropathy (PN) in most diabetic patients. We hypothesized that a FDA cleared medical device, which emits monochromatic near infrared (890 nm) photo energy (MIRE) would improve neural function lost during diabetes. Research Design arid Methods: 49 consecutive diabetic subjects (Type 1. n=25: Type II, n=24). with established neuropathy received MIRE treatment to determine if there was an improvement of sensation. All had PN classified as either absent. diminished, or impaired protective sensation assessed by the Semmes-Weinstein (SW) monofilament test or hot/cold (H/C) sensation impairment. Impaired protective sensation, (4.56 or above) was present in 100% of subjects (range: 4.56-6.45) and 42 of 49 subjects had SW values exceeding 5.07. reported to be one of the most sensitive predictors of eventual diabetic foot ulceration. H/C sensation was absent (54%) or impaired (46%) prior to initiating treatment. The MIRE diode array was placed in contact with the skin on the lower leg/foot for 30 min./day, 3X/week for one month. SW and H/C tests were repeated at two and four weeks.